Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases:

Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension

This study will enroll approximately 60 subjects in stage I and 60 subjects in stage II with hematologic or solid tumor malignancies, excluding gastrointestinal tumors and tumors that have originated or metastasized to the liver for which no standard treatment exists or have progressed or recurred following prior therapy. Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population. Approximately 23 sites in the US and 2 in Canada will participate in this study.

Study Overview

• Status: Completed
• Conditions: Melanoma; Sarcoma; Neoplasms; Lymphoma; Renal Cell Carcinoma; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Leukemia; Breast Cancer; Small Cell Lung Cancer; Multiple Myeloma; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer; Osteosarcoma; Glioblastoma Multiforme; Metastatic Breast Cancer; Thyroid Cancer; Hematological Neoplasms; Genitourinary
• Intervention / Treatment: Drug: CC-486; Drug: Vidaza

Detailed Description

Stage I - Pharmacokinetics (Bioequivalence)

Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to:

Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet followed by 2x150 mg tablets. Each dose will be administered in the clinic at least 48 hours apart between PK dosing day 1 and PK dosing day 2 over a period no longer than 10 days under fasted conditions.

Stage II - Pharmacokinetics (Food Effect)

Subjects will be randomized to receive CC-486 300 mg orally on each of the two PK study days based on the dosing sequences they are randomized to:

Dosing Sequence 1: 1x300 mg tablet under fasted condition followed by 1x300 mg tablet under fed condition.

Dosing Sequence 2: 1x300 mg tablet under fed condition followed by 1x300 mg tablet under fasted condition.

Each dose will be administered in the clinic at least 48 hours apart between PK dosing day 1 and PK dosing day 2 over a period no longer than 10 days. The sponsor will generate the randomization scheme and assign subjects upon enrollment to the appropriate sequence for dosing:

Fasted condition: following an overnight fast of at least 10 hours, subjects will ingest oral Azacitidine with 240 mL of room temperature water. Subjects must fast for a minimum of 4 hours following oral Azacitidine administration. Subjects may drink water as desired, except for 1 hour before and 1 hour after oral Azacitidine administration.

Fed condition: following an overnight fast of at least 10 hours and following the performance of all required pre-dose assessments, subjects randomized to receive test medication in a fed state will begin ingesting a breakfast meal 30 (±5) minutes prior to the planned administration of oral Azacitidine. They will continue the entire meal within 20 to 25 minutes (no less than 20 minutes) from the time the meal is served. Subjects will then ingest oral Azacitidine with 240 mL of room temperature water. Subjects must fast a minimum of 4 hours following oral Azacitidine administration. Subjects may drink water as desired, except for 1 hour before and 1 hour after administration of oral Azacitidine.

Extension Phase (for subjects who have completed PK Stage I or Stage II) Subjects continuing beyond the pharmacokinetics phase (Stage I or Stage II) will enter the extension phase of the study at the discretion of the investigator to receive < 6 (four-week) cycles of Vidaza 75 mg/m2 IV or SC daily for 7 days in the clinic and repeat every 4 weeks per prescribed label at the discretion of the investigator for ≤ 6 (four-week) cycles.

• Study Type: Interventional
• Enrollment (Actual): 89
• Phase: Phase 1

Expanded Access

Approved for sale to the public. See expanded access record.

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85259
      • Mayo Clinic - Arizona
    • Scottsdale, Arizona, United States, 85258
      • Scottsdale Healthcare Research Institute
    • Tucson, Arizona, United States, 85724
      • University of Arizona Cancer Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa
  • Michigan
    • Detroit, Michigan, United States, 48202-268
      • Henry Ford Health System
  • New Jersey
    • New Brunswick, New Jersey, United States, 08903
      • Cancer Institute Of New Jersey
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Greenville Hospital System
  • Tennessee
    • Nashville, Tennessee, United States, 37232-6307
      • Vanderbilt- Ingram Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • The Methodist Hospital Research Institute l

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects must satisfy the following criteria to be enrolled in the study:

  1. Age ≥ 18 years of age at the time of signing the informed consent document.
  2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.

  3. Documented diagnosis of any of the following:

     1. Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classification
     2. Acute myeloid leukemia (AML)
     3. Multiple myeloma (MM), limited to those patients for whom standard curative or palliative treatments do not exist or are no longer effective
     4. Non-Hodgkin's lymphoma (NHL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective,
     5. Hodgkin's lymphoma (HL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective

     6. Metastatic or inoperable solid tumors* (except gastrointestinal tumors or tumors that originated or metastasized to the liver) for which no standard treatment exists, or have progressed or recurred following prior therapy.

        • Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population.
  4. Patients with a history of treated brain metastases should be clinically stable for ≥ 4 weeks prior to signing the informed consent. Glucocorticoid therapy for central nervous system (CNS) edema is permitted if ≤ 20 mg of prednisolone (or equivalent).
  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  6. Have a life expectancy of ≥ 3 months.

  7. Have stable renal function without dialysis for at least 2 months prior to Investigational Product (IP) administration defined by:

     1. Serum creatinine < 2.5 x the upper limit of normal (ULN)
     2. An average calculated creatinine clearance > 30 mL/min/1.73 m^2

  8. Have organ and marrow function at the screening and pre-dose visits as defined by:

     1. Hemoglobin ≥ 8 g/dL
     2. Absolute neutrophil count (ANC) ≥ 0.75 x 10^3/uL without treatment with a myeloid growth factor within 3 days prior to first dose of IP
     3. Platelets ≥ 30 x 10^3/uL
     4. Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN)
     5. Aspartate aminotransferase (AST) ≤ 2 x ULN
     6. Alanine aminotransferase (ALT) ≤ 2 x ULN
  9. Have a 12-lead Electrocardiogram (ECG) that is not clinically significant at screening, as determined by the investigator

  10. Females of childbearing potential (FCBP) may participate, providing the subject meets the following conditions:

      • Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) or agree to practice true abstinence throughout the study, and for 3 months following the last dose of IP; and
      • Negative serum pregnancy test at screening (sensitivity of at least 25 mIU/mL); (Note that the screening serum pregnancy test can be used as the test prior to starting IP in the pharmacokinetics phase if it is performed within the 72-hour timeframe), and
      • Negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) within 72 hours prior to starting IP in the extension phase. (Note: subjects must have negative serum or urine pregnancy test prior to dosing on Day 1 of each treatment cycle in the extension phase.)

  11. Male subjects must:

      a. Practice true abstinence* or agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study for at least 3 months following the last dose of IP.

      * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].

  12. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Women who are pregnant or nursing (lactating).
2. Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
3. Had chemotherapy or radiotherapy within 4 weeks prior to the first day of Investigational Product (IP) administration.
4. Have been treated with an investigational agent within 4 weeks prior to the first day of IP administration.
5. Have ongoing clinically significant adverse event(s) due to prior treatments administered as determined by the investigator.

6. Significant active cardiac disease within the previous 6 months, including:

   • New York Heart Association (NYHA) class IV congestive heart failure
   • Significant cardiac arrhythmia or unstable angina or angina requiring surgical or medical intervention; and/or
   • Myocardial infarction
7. Have known or suspected hypersensitivity to azacitidine or any other ingredient used in the manufacturing of Azacitidine.
8. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
9. History of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
10. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
11. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
12. Any condition that confounds the ability to interpret data from the study
13. Impaired ability to swallow oral medication
14. Any condition that confounds the ability to interpret data from the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1; Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.	Drug: CC-486; Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2; Other Names: Oral Azacitdine; Drug: Vidaza; 75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles; Other Names: AZA; Azacitidine for Injection
Experimental: CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1; One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.	Drug: CC-486; Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2; Other Names: Oral Azacitdine; Drug: Vidaza; 75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles; Other Names: AZA; Azacitidine for Injection
Experimental: CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2; One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.	Drug: CC-486; Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2; Other Names: Oral Azacitdine; Drug: Vidaza; 75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles; Other Names: AZA; Azacitidine for Injection
Experimental: CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2; One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.	Drug: CC-486; Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2; Other Names: Oral Azacitdine; Drug: Vidaza; 75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles; Other Names: AZA; Azacitidine for Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics Cmax - Stage I (Bioequivalence)	The observed maximum concentration	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Tmax - Stage I (Bioequivalence)	The observed time to first maximum concentration	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics AUC-t - Stage I (Bioequivalence)	Area under the concentration-time curve from time zero to the last quantifiable time point calculated by the linear trapezoidal rule	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)	Area under the concentration time-curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity. It will be calculated as AUC∞ = [AUCt + Ct/λz]. Ct is the last quantifiable concentration	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)	Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear concentration-time curve	Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)	Terminal phase half-life, calculated according to the following equation: t½ = 0.693/λz	Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)	Apparent total clearance, calculated as Dose/AUC∞	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)	Apparent volume of distribution, calculated according to the equation: Vd/F = (CL/F) / λz	Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)	The observed maximum concentration	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)	The observed time to first maximum concentration	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)	Area under the concentration-time curve from time zero to the last quantifiable time point calculated by the linear trapezoidal rule.	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)	Area under the concentration time-curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity. It will be calculated as AUC∞ = [AUCt + Ct/λz]. Ct is the last quantifiable concentration.	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)	Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear concentration-time curve	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)	Terminal phase half-life, calculated according to the following equation: t½ = 0.693/λz	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)	Apparent total clearance, calculated as Dose/AUC∞	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)	Apparent volume of distribution, calculated according to the equation: Vd/F = (CL/F) / λz	PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Adverse Event (AE) is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an AE.	Up to 18 months

Collaborators and Investigators

• Sponsor: Celgene
• Investigators: Study Director: Du Lam, MD, Celgene

Study record dates

Study Major Dates

• Study Start (Actual): October 27, 2014
• Primary Completion (Actual): June 11, 2018
• Study Completion (Actual): December 18, 2018

Study Registration Dates

• First Submitted: August 20, 2014
• First Submitted That Met QC Criteria: August 20, 2014
• First Posted (Estimate): August 22, 2014

Study Record Updates

• Last Update Posted (Actual): May 12, 2020
• Last Update Submitted That Met QC Criteria: May 11, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Keywords: Breast Cancer; Survival; Acute Myeloid Leukemia; Multiple Myeloma; NSCLC; Non-Small Cell Lung Cancer; Neoplasms; Glioblastoma Multiforme; GBM; Lymphoma; Prostate Cancer; AML; Lung cancer; NHL; Skin Cancer; Melanoma; Leukemia; Chemotherapy; Ovarian Cancer; MDS; Myelodysplastic Syndromes; MM; Metastatic Breast Cancer; Brain Cancer; Bladder Cancer; Kidney Cancer; Small Cell Lung Cancer; Bone Metastasis; MBC; HL; Hematological Malignancy; SCLC; Renal Cell Carcinoma; Genitourinary; Targeted Therapy; Thyroid Cancer; Blood Cancer; CC-486; Oral Azacitidine; Soli Tumor Malignancy; Bone Cancer; Testicular Cancer; Cancer general
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Respiratory Tract Diseases; Immune System Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lung Diseases; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Endocrine System Diseases; Bone Marrow Diseases; Hematologic Diseases; Endocrine Gland Neoplasms; Breast Diseases; Hemorrhagic Disorders; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Thyroid Diseases; Head and Neck Neoplasms; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Kidney Neoplasms; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Neoplasms, Plasma Cell; Precancerous Conditions; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Sarcoma; Neoplasms; Lymphoma; Carcinoma, Renal Cell; Myelodysplastic Syndromes; Breast Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Multiple Myeloma; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Small Cell Lung Carcinoma; Melanoma; Osteosarcoma; Thyroid Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Azacitidine; Cc-486
• Other Study ID Numbers: CC-486-CAGEN-001